Autor: |
Wang Xiang-Yang, Wang Ena, Graham Laura, Ascierto Maria-Libera, Grimes Margaret M, Idowu Michael O, Payne Kyle K, Kmieciak Maciej, Bear Harry D, Manjili Masoud H |
Jazyk: |
angličtina |
Rok vydání: |
2011 |
Předmět: |
|
Zdroj: |
Journal of Translational Medicine, Vol 9, Iss 1, p 35 (2011) |
Druh dokumentu: |
article |
ISSN: |
1479-5876 |
DOI: |
10.1186/1479-5876-9-35 |
Popis: |
Abstract Background Emerging data from pre-clinical and clinical studies suggest that HER-2/neu-specific T cell responses could induce HER-2/neu antigen loss in the tumor cells. These data suggest that patients with HER-2/neu negative breast cancer might have had HER-2/neu positive premalignant lesions in the past that progressed to HER-2/neu negative breast cancer under HER-2/neu-specific immune pressure. Methods We conducted a pilot study in patients with HER-2/neu positive and HER-2/neu negative breast cancers as well as a patient with ductal carcinoma in situ (DCIS). HER-2/neu expression was determined by FISH. HER-2/neu-specific T cell responses were determined by using IFN-γ ELISA. Expression of IFN-γ Rα in the tumors was determined by immunohistochemistry analysis of paraffin-embedded tissues. Results We determined that majority of (10 of 12) patients with HER-2/neu negative breast cancer had HER-2/neu-specific IFN-γ producing T cell responses which was stronger than those in patients with HER-2/neu positive tumors. Such immune responses were associated with nuclear translocation of IFN-γ Rα in their tumor cells. Patient with DCIS also showed HER-2/neu-specific T cell responses. Conclusion These data suggest that conducting retrospective studies in patients with HER-2/neu negative breast cancers and prospective studies in patients with HER-2/neu positive DCIS can determine whether HER-2/neu negative invasive carcinomas arise from HER-2/neu positive DCIS under the immune pressure. |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|